close

Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally. The company develops and commercializes prescription-based, topical skin health systems, which enable physicians to treat a range of skin conditions. It offers Obagi Nu-Derm System, which includes prescription and OTC drugs that are used for the treatment of fine lines, wrinkles, acne, photo-damage, hyper pigmentation, melasma, laxity, and skin sallowness; Obagi Condition and Enhance Systems, which are used before and after surgical and non-surgical cosmetic procedures; Obagi-C Rx System, a combination of prescription, OTC drugs, and adjunctive cosmetic skin care products to treat skin conditions resulting from sun damage and the oxidative damage of free radicals; and Obagi Professional-C products, a line of proprietary, non-prescription products, which consist of vitamin C serums used to reduce the appearance of damage to the skin caused by ultraviolet radiation and other environmental influences. The company also offers ELASTIderm Eye and Decolletage, which increases the elasticity and skin tone of eyes, face, neckline, and chest; CLENZIderm M.D. Systems and SoluCLENZ Rx Gel for the treatment of acne; Obagi Rosaclear System, which is used for treating rosacea that reduces redness and flushing, as well as for the treatment of papules and pustules; Tretinoin, which is used for the treatment of acne in the United States; and Obagi Blue Peel System that is used for the treatment of fine lines, wrinkles, and hyper pigmentation. It markets its products through its domestic sales force and foreign distribution partners, as well as through the physician-dispensed skin channel to plastic surgeons, dermatologists, and other physicians that are focused on aesthetic and therapeutic skin care. The company was founded in 1988 and is headquartered in Long Beach, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	12.59
Volume	84533
Volume Avg	97072
52 Week High	13.60
52 Week Low	8.61
PE	23.43
PE (group average)	N/A
EPS Year	0.54
EPS change Q/Q	1000%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	163.64%
REV change Q/Q	-12.54%
REV change Q/Q Yr ago	3.11%
EPS next Q est	0.23
EPS next Y est	0.99
Divident Annual	0.00
Dividend Yield	0%